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Aim: To analyze an expression pattern of the steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes 
in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion; and to examine a putative correlation between gene 
expression and clinical characteristics, to define the molecular subtypes of prostate cancer. Materials and Methods: The relative gene 
expression (RE) of 33 transcripts (27 genes) and the presence/absence of the TMPRSS2/ERG fusion were analyzed by a quan-
titative PCR. 37 prostate cancer tissues (T) paired with conventionally normal prostate tissue (CNT) and 21 samples of prostate 
adenomas were investigated. RE changes were calculated, using different protocols of statistics. Results: We demonstrated differences 
in RE of seven genes between tumors and CNT, as was calculated, using the 2−ΔCT model and the Wilcoxon matched paired test. 
Five genes (ESR1, KRT18, MKI67, MMP9, PCA3) showed altered expression in adenocarcinomas, in which the TMPRSS2/ERG 
fusion was detected. Two genes (INSR, isoform B and HOTAIR) expressed differently in tumors without fusion. Comparison of the 
gene expression pattern in adenomas, CNT and adenocarcinomas demonstrated that in adenocarcinomas, bearing the TMPRSS2/
ERG fusion, genes KRT18, PCA3, and SCHLAP1 expressed differently. At the same time, we detected differences in RE of AR 
(isoform 2), MMP9, PRLR and HOTAIR in adenocarcinomas without the TMPRSS2/ERG fusion. Two genes (ESR1 and SRD5A2) 
showed differences in RE in both adenocarcinoma groups. Fourteen genes, namely AR (isoforms 1 and 2), CDH1, OCLN, NKX3-1, 
XIAP, GCR (ins AG), INSR (isoform A), IGF1R, IGF1R tr, PRLR, PRL, VDR and SRD5A2 showed correlation between RE and 
tumor stage. RE of four genes (CDH2, ESR2, VDR and SRD5A2) correlated with differentiation status of tumors (Gleason score). 
Using the K-means clustering, we could cluster adenocarcinomas in three groups, according to gene expression profiles. A specific 
subtype of prostate tumors is characterized by the activated ERG signaling, due to the presence of TMPRSS2/ERG fusion, and 
also by high levels of the androgen receptor, prolactin, IGF, INSR and PCA3. Conclusions: We have found the specific differences 
in expression of the steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes, depending on the pre-
sence/absence of the TMPRSS2/ERG fusion in prostate adenocarcinomas, CNT and adenomas. We showed three different gene 
expression profiles of prostate adenocarcinomas. One of them is characteristic for adenocarcinomas with the TMPRSS2/ERG 
fusion. Further experiments are needed to confirm these data in a larger cohort of patients.
Key Words: prostate tumors, TMPRSS2/ERG fusion, gene expression patterns, steroid receptors, peptide receptors, EMT 
regulation.
Alterations in expression of the androgen recep-
tor (AR) are often associated with development 
of prostate cancer. It is known already that the AR gene 
expression is regulated by quite many molecular 
pathways [1]. Another example of frequent altera-
tions in prostate tumors is formation of gene fusions 
of androgen dependent gene TMPRSS2 (transmem-
brane protease, serine 2) with the ETS (E26 transfor-
mation-specific) family in particular with ERG (ETS 
related gene) [2]. Previously, we have shown that the 
TMPRSS2/ERG fusion is present in prostate adeno-
carcinoma and even in conventionally normal prostate 
tissue (CNT) in a group of patients of the Ukrainian 
population [3]. Therefore, we may speculate that the 
presence or absence of the gene fusions could be the 
cause of development of various prostate cancer 
types with different sensitivity to therapy, recurrence 
and metastasizing, despite the similar histological 
characteristics [4].
One of the important characteristics of normal 
functioning of prostate epithelial cells is sensitivity 
to steroid and peptide hormones. In the process of cell 
transformation, tumor cells often lose the sensitivity 
to hormones and growth factors and also change their 
metabolism. The AR is a key element of prostate func-
tioning and is involved in malignant transformation. 
As was shown already, AR signaling plays a primary role 
in development of androgen resistant and castration-
resistant prostate cancer [1]. There are few isoforms 
of ARs. Some of them are prostate specific. AR expres-
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sion can change during prostate carcinogenesis. Thus, 
the overexpression of AR isoform A (1 isof) decreases 
proliferation but accelerates invasion of prostate 
cancer cells, compared with overexpression of AR iso-
form B (2 isof) [5]. Also, it was proposed that forma-
tion of the fusion between TMPRSS2 and ERG might 
be controlled by androgens [6].
In prostate cells, the most potent AR ago-
nist is dihydrotestosterone. This is a metabolite 
of testosterone, and the reaction of conversion 
is catalyzed by SRD5A1 (5α-reductase, type 1) 
and SRD5A2 (5α-reductase, type 2). The latter are 
expressed at low levels in normal prostate tissues, 
but upon prostate cancer progression expression 
of these enzymes is altered [7]. Noteworthy, pros-
tate cancer is a complex pathology and many other 
hormone receptors and corresponding pathways 
are involved in tumor development, especially GCR 
(glucocorticoid receptor, NR3C1 nuclear receptor 
subfamily 3 group C member 1), IGF1R (insulin like 
growth factor 1 receptor), ESR1 and ESR2 (estrogen 
receptors 1 and 2), PRLR (prolactin receptor), VDR 
(vitamin D receptor) and others.
Of note, GCR and AR share several transcriptional 
targets [8]. All of the three isoforms of GCR (alpha (A), 
beta (B) and gamma (G)) are very important in de-
velopment and progression of prostate cancer [9]. 
In initiation and also in progression of the prostate 
cancer the IGF network, including INSR (insulin recep-
tor) — (subtypes INSR A and B), IGF1R and IGF2R 
plays an important role [10–12].
Both estrogen receptors, alpha (ESRα, ESR1) 
and beta (ESRβ, ESR2) are associated with deve-
lopment of prostate cancer [13]. It was shown, that 
the increased expression of ESRα is observed upon 
progression, metastasizing, and in androgen resistant 
phenotype; ESRα could be involved in regulation of ex-
pression of the TMPRSS2-ERG fusion [14].
PRL (prolactin) can induce growth and survival 
of prostate cancer cells [15]. The PRL expression cor-
relates with the disease severity.
It was shown that vitamin D (calcitriol) influences 
on prostate cancer cells growth [16]. Furthermore, the 
TMPRSS2-ERG fusion expression is increased upon 
activation of VDR and AR. Consequently, expression 
of TMPRSS2/ERG leads to inactivation of the VDR 
signaling [17].
We have shown earlier that several genes, regu-
lating the epithelial-to-mesenchymal cell transi-
tion (EMT), such as CDH1, CDH2, NKX3-1, FN1 and 
VIM, are expressed differently in prostate tumors [18].
In a present work, we aimed to analyze the expres-
sion pattern of a group of the cancer-related genes, de-
pending on the presence or absence of the TMPRSS2/
ERG fusion in prostate tumors. Also, we wanted to find 
the putative correlations between gene expression pat-
terns and clinical and pathological characteristics (CPC) 
to define the molecular subtypes of prostate cancer.
MATERIALS AND METHODS
A collection of prostate tissues samples. 
Samples of cancer tissue and CNT (at an opposite side 
of tumor) were frozen in liquid nitrogen immediately 
after surgical resection at the National Cancer Insti-
tute (Kyiv, Ukraine). Benign prostate tumors (prostate 
adenoma samples) were collected at the Institute 
of Urology (Kyiv, Ukraine) after radical prostatectomy 
and frozen, as described above. The samples were 
collected in accordance with the Declaration of Hel-
sinki and the guidelines issued by the Ethic Committee 
of the Institute of Urology, the National Cancer Institute 
and an Ethic Committee of the Institute of Molecular 
Biology and Genetics. Experimental studies were 
conducted on 37 prostate adenocarcinoma samples 
of different Gleason score and stages; 37 paired CNT 
samples; 21 samples of benign prostate tumors (ade-
nomas). Tumor samples were characterized, according 
to an International System of Classiﬁcation of Tumors, 
based on the tumor-node-metastasis (TNM) and the 
World Health Organization (WHO) criteria. CPC and the 
presence/absence of the TMPRSS2/ERG fusion, that 
we have detected earlier [3] are presented on Table 1.
Table 1. CPC and TMPRSS2/ERG status (T/ERG) of prostate adenocarci-
noma samples
Sample number T/ERG Stage Gleason score TNM PSA, ng/ml
1 – ІІ < 7 T2bN0M0 12.8
2 – ІІ < 7 T2сNxM0 27.3
3 – ІІІ < 7 T3bNхM0 23.6
4 – ІІ < 7 T2bNxM0 6.5
5 – II < 7 T2cNxM0 25.2
6 + ІІ < 7 T2аNxM0 18.6
7 + ІІ < 7 T2аN0M0 9.3
8 + ІІ < 7 T2aN0M0 6.0
9 + II < 7 T2pN0M0 5.0
10 + ІІ < 7 T2аN0M0 13.3
11 + II < 7 T2cN0M0 29.1
12 – ІІ 7 T2аNxM0 11.7
13 – ІІ 7 T2сNxM0 13.9
14 – ІІ 7 T2сNxM0 19.8
15 + ІІ 7 T2аNxM0 7.1
16 + І 7 T1сNxM0 8.2
17 + ІІ 7 T2сNxM0 19.3
18 + ІІ 7 T2аNхM0 5.6
19 + ІІ 7 T2cN0M0 14.3
20 + ІІІ 7 T2bN0M0 24.6
21 – ІІІ > 7 T3bNхM0 86.3
22 – ІV > 7 T3aN0M1 37.8
23 – IV > 7 T2сN0M1 22.6
24 – ІІІ > 7 T2сN1M0 2.3
25 – ІІ > 7 T2bNxM0 6.9
26 – III > 7 T3bNxM0 51.0
27 – ІІІ > 7 T2bNxM0 0.5
28 – ІІ > 7 T2bN0M0 20.3
29 + ІІ > 7 T2cN0M0 9.7
30 + IІІ > 7 T3bN0M0 12.1
31 + III > 7 T3aN0M0 25.1
32 + ІІІ > 7 T3bNхM0 16.0
33 + ІІI > 7 T3bN0M0 84.2
34 + ІІІ > 7 Т3bNхМ0 20.9
35 + IV > 7 T2cN1M0 17.0
36 + ІІ > 7 T2bNxM0 33.0
37 + ІІІ > 7 T3bNxM0 106.0
Note: + presence of TMPRSS2/ERG fusion; − absence of TMPRSS2/ERG 
fusion.
Total RNA isolation and cDNA synthesis. 
50–70 mg of frozen prostate tissues were mashed 
to a powder in the liquid nitrogen. Total RNA was 
extracted by TRI- reagent (SIGMA), according to the 
manufacturer’s protocol. Total RNA concentration was 
analyzed by a spectrophotometer (NanoDrop Tech-
Experimental Oncology 40, 101–108, 2018 (June) 103
nologies Inc., USA). The quality of the total RNA was 
determined in a 1% agarose gel by band intensity of 28S 
and 18S rRNA (28S/18S ratio). cDNA was synthesized 
from 1 µg of the total RNA, that was treated with the 
RNase free DNase I (Thermo Fisher Scientific, USA), 
using RevertAid H-Minus M-MuLV Reverse Transcrip-
tase (Thermo Fisher Scientific, USA), according to the 
manufacturer’s protocol.
Quantitative quantitative polymerase chain re-
action (qPCR). Relative gene expression (RE) levels 
of 27 genes (33 transcripts) were detected by qPCR, 
using Maxima SYBR Green Master mix (Thermo Fisher 
Scientific, USA) and Bio-Rad CFX96 Real-Time PCR 
Detection System (USA) under the following condi-
tions: 95 °C — 10 min, following 40 cycles of 95 °C — 
15 s, 60 °C — 30 s, elongation 72 °C — 30 s. Primers 
for the different transcripts of INSR and IGF1R and 
various isoforms of GCR were as published earlier [9, 
19]. Primers for others genes were selected, using 
qPrimerDepot (https://primerdepot.nci.nih.gov/).
Four reference genes — TBP, HPRT, ALAS1 and 
TUBA1B — were used for normalization of the gene 
expression [20]. The two main models (2-ΔCT and 2-ΔΔCT 
methods), described earlier [18, 21], were used for the 
RE level calculation and analysis.
Statistical analysis. The Kolmogorov — Smirnov 
test was used to analyze the normality of distribution. 
The Kruskal — Wallis test was used to determine 
differences by multiple comparison between experi-
mental groups. The Wilcoxon Matched Pairs test was 
performed to compare RE in prostate adenocarcinoma 
and paired CNT. RE fold differences in 2-ΔΔCT model 
were considered significant when expression changes 
were more, than 2 fold. The Fisher exact test was per-
formed to monitor differences between these sample 
groups [21]. The Benjamini — Hochberg procedure 
with false discovery rate (FDR) 0.10–0.25 was used 
when multiple comparisons were performed [22]. 
The Dunn — Bonferroni post hoc test was performed 
to determine RE differences between pairs of prostate 
samples. The Spearman’s rank correlation test was 
used to find the putative correlations between RE and 
CPC of prostate tumors and also correlations between 
RE of investigated genes. The K-Mean clustering was 
applied for prostate cancer subtyping and also for 
the specific gene expression profiles, following by the 
Kruskal — Wallis and Dunn — Bonferroni post hoc tests 
for detection of inter-cluster differences in RE.
RESULTS
Expression of 17 transcripts (11 genes), represent-
ing the receptors and metabolic enzymes and also 
16 EMT-related transcripts/genes (3 from them are 
lncRNAs) were studied in prostate adenocarcinomas, 
CNT and adenomas.
Earlier, we have shown that the TMPRSS2/ERG fu-
sion was expressed in 21 out of 37 adenocarcinomas [3]. 
In this group, in 16 paired CNT the TMPRSS2/ERG fusion 
was detected, and 5 CNT did not show this fusion. Thus, 
we have 3 groups in a set of the paired adenocarcinomas/
CNT: 1) T–/N– group — the TMPRSS2/ERG fusion was 
not detected neither in adenocarcinomas nor in CNT 
(n = 16); 2) T+/N+ group — the TMPRSS2/ERG fusion 
was found in both, cancer and CNT (n = 16); 3) T+/N– 
group — the TMPRSS2/ERG fusion was present in ad-
enocarcinomas, but not in CNT (n = 5).
The Wilcoxon Matched paired test in the 2-ΔCT 
model showed the differences in RE of 7 genes, when 
the paired adenocarcinoma (T) and CNT (N) were 
compared, regardless presence or absence of the 
TMPRSS2/ERG fusion (Table 2).
Table 2. RE differences between prostate adenocarcinoma samples 
and paired CNT with and without fusion status detection (dependent sam-
pling, 2−ΔCT model)
Gene
Pairs with differences 
without fusion status  
detection
p-value&
Pairs with dif-
ferences with 
fusion status
p-value&
ESR1 T/N 0.010 T+/N+ 0.038
T+/N– 0.043
INSR
(B isof)
T/N 0.037 T–/N– 0.039
KRT18 T/N 0.000 T+/N+ 0.007
MKI67 T/N 0.017 T+/N+ 0.003
MMP2 T/N 0.011 no –
MMP9 T/N 0.014 T+/N+ 0.011
VIM T/N 0.010 no –
HOTAIR T/N 0.007 T–/N– 0.027
PCA3 no – T+/N+ 0.049
Note: &Wilcoxon Matched Pairs test significant with FDR = 0.1.
The following five genes were upregulated in ad-
enocarcinomas, when T/N pairs with the fusion in both, 
tumor and CNT were analyzed: ESR1 (p = 0.038), 
Table 3. Frequency of RE fold changes (2−ΔΔCT) in prostate adenocarcinoma (T) in comparison with paired CNT (N) in groups with different TMPRSS2/ERG 
status and statistical significant differences in paired T/CNT in 2−ΔCT model
Group N RE fold changes
AR 
(1isof)
AR 
(2isof) ESR1 ESR2
GCR 
(AG isof)
GCR
(in AG)
GCR
(in B)
INSR
(A isof)
INSR
(B isof) IGF1R IGF1R tr PRLR PRL SRD5A1 SRD5A2 VDR
1 T–/
N–
16 < 0.49 1 4 3 2 0 1 0 0 0 1 3 4 4 2 1 3
> 2.10 1 2 7$ 4 0 0 2 2 4# 2 1 1 2 0 0 1
2 T+/
N+
16 < 0.49 3 2 1 3 0 1 1 3 0 3 1 1 0 3 4 2
> 2.10 1 2 9$ # 1 1 1 1 0 1 1 0 1 1 2 1 3
3 T+/
N–
5 < 0.49 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
> 2.10 0 1 3# 2 0 0 0 0 2 1 0 0 0 1 0 0
Group N RE fold changes CDH1 CDH2 FN1 VIM OCLN MMP2 MMP9 NKX3-1 PSA KRT18 MKI67 CASP3 XIAP PCA3 HOTAIR SCHLAP1
1 T–/N– 16 < 0.49 4 2 3 1 2 0 1 6 5 2 3 1 0 6 2 6
> 2.10 0 3 3 3 3 1 5 1 3 2 2 0 2 4 9$ # 6
2 T+/N+ 16 < 0.49 5 6 0 0 3 1 0 5 2 0 1 1 0 4 2 3
> 2.10 0 2 2 3 4 3 9$ # 2 1 5# 7$ # 2 0 9$ # 7$ 7$
3 T+/N– 5 < 0.49 1 2 0 0 0 0 1 0 1 0 1 0 0 0 1 0
> 2.10 2 0 0 1 2 0 1 1 1 1 2 0 0 4$ 1 2
Notes: $statistical significant differences between adenocarcinoma and CNT groups by Fisher exact test (p < 0.05) (2–ΔΔCT);
#statistical significant differences between adenocarcinoma and CNT groups by Wilcoxon Matched Pairs test (p < 0.05) (2–ΔCT).
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KRT18 (p = 0.007), MKI67 (p = 0.003), MMP9 (p = 0.011) 
and PCA3 (p = 0.049). In adenocarcinomas without fu-
sion INSR (B isof) (p = 0.039) and HOTAIR (p = 0.027) 
were expressed at the higher levels, than in the paired 
CNT. Only one gene, ESR1, showed significant chang-
es in RE in adenocarcinomas with the presence of the 
fusion, compared with CNT without fusion (p = 0.043).
When the 2-ΔΔCT model was used, we found 6 genes 
with significant differences in RE between adenocarci-
nomas and CNT (Table 3). Three genes (MMP9, MKI67, 
and SCHLAP1) where expressed at the higher levels 
in tumors, compared with CNT (the T+/N+ group) 
(p < 0.05), two genes (ESR1 and HOTAIR) have shown 
increased RE in T+/N+ and T–/N– groups (p < 0.05). 
Only one gene, the PCA3 was significantly increased 
in T+/N+ and T+/N– groups (p < 0.05).
Hence, the data obtained by the two abovemen-
tioned models are only partially overlapping. This could 
be due to different statistical calculations.
Earlier, we have discussed that CNT isolated from 
patients with prostate tumors do not represent the 
normal tissue, therefore they can’t be considered 
as an adequate control [18]. In order to avoid working 
with inadequate controls, adenomas were used as the 
control instead. Noteworthy, the TMPRSS2/ERG fusion 
was detected in 4 adenomas as well. No differences 
in the gene expression patterns were found in these 
Table 4. RE differences between pairs of groups with different TMPRSS2/
ERG status
Gene/transcript p-value* Pairs with differences p-value**
AR (2 isof) 0.024 T–/A 0.017
ECR1 < 0.001 T–/A 0.002
T+/A < 0.001
N–/A 0.040
PRLR 0.017 T–/A 0.009
SRD5A2 0.002 T–/A 0.039
T+/A 0.003
N+/A 0.020
KRT18 0.007 T+/A 0.008
MMP9 0.001 T–/A 0.003
N–/A 0.012
OCLN 0.021 no –
VIM 0.045 no –
PCA3 0.001 T+/A 0.001
N+/A 0.001
HOTAIR 0.003 T–/A 0.002
SCHLAP1 0.010 T+/A 0.011
Notes: *Kruskal — Wallis test data significant with FDR = 0.1;
**Dunn — Bonferroni post hoc method for multiple comparisons.
Fig. 1. RE of genes with significant differences between 5 groups with presence (+) or absence (–) of fusion transcript. 
*p < 0.05 in comparision with adenomas group (A) (Dunn — Bonferoni post hoc test for multiple comparisions)
AR (2 isof)
 Median 
 25%-75% 
 Min-Max 
T- T+ N- N+ A
0.002
0.003
0.004
0.005
0.006
0.007
0.008
0.009
0.010
0.020
0.030
0.040
0.050
0.060
0.070
0.080
0.090
0.100
RE
, 2
 -∆
C T
,r.
u. *
ESR1
T- T+ N- N+ A
0.0050
0.0075
0.0250
0.0500
0.0750
0.2500
0.5000
0.7500
2.5000
RE
, 2
 -∆
C T
,r.
u.
*
*
*
PRLR
T- T+ N- N+ A
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
2.00
RE
, 2
 -∆
C T
,r.
u.
*
SRD5A2
T- T+ N- N+ A
0.04
0.05
0.06
0.07
0.08
0.090.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.901.00
2.00
3.00
4.00
RE
, 2
 -∆
C T
,r.
u.
* **
KRT18
T- T+ N- N+ A
0.50
0.75
2.50
5.00
7.50
25.00
50.00
75.00
RE
, 2
 -∆
C T
,r.
u.
*
MMP9
T- T+ N- N+ A
0.05
0.50
5.00
RE
, 2
 -∆
C T
,r.
u.
*
*
PCA3
T- T+ N- N+ A
0.0005
0.0050
0.0500
0.5000
5.0000
50.0000
RE
, 2
 -∆
C T
,r.
u.
*
*
HOTAIR
T- T+ N- N+ A
5E-5
0.0005
0.0050
0.0500
0.5000
RE
, 2
 -∆
C T
,r.
u.
*
SCHLAP1
T- T+ N- N+ A
0.0005
0.0050
0.0500
0.5000
5.0000
RE
, 2
 -∆
C T
,r.
u.
*
Experimental Oncology 40, 101–108, 2018 (June) 105
4 adenomas, compared with adenomas without fusion. 
For further comparison, only the group of adenomas 
without fusion was analyzed (n = 17). Also, CNT samples 
without fusion (n = 5) from adenocarcinoma pairs with 
the fusion were attributed to total CNT fusion negative 
(N–) group after verification of RE differences in CNT 
sample groups for all investigated genes.
The Kruskal — Wallis test (with FDR = 0.1) has shown 
significant differences of RE in 11 out of 33 trans cripts/
genes between 5 investigated groups (T+, T–, N+, N– 
and A–), while the Dunn — Bonferroni post hoc method 
of the multiple comparisons has confirmed changes 
only for 9 transcripts/genes (Table 4, Fig. 1).
Increased RE levels in the adenocarcinoma 
and CNT groups, compared to the adenoma group 
was shown for 6 genes 1) ECR1 T–/A– group 
(p = 0.002), T+/A– (p < 0.001), N–/A– (p = 0.040); 
2) KRT18 T+/A– (p = 0.008); 3) MMP9 T–/A– (p = 0.003), 
N–/A– (p = 0.012); 4) PCA3 T+/A– (p = 0.001), 
N+/A– (p = 0.001); 5) HOTAIR T–/A– (p = 0.002), and 
6) SCHLAP1 T+/A– (p = 0.011). Decreased RE levels 
in the adenocarcinoma and CNT groups, compared 
to the adenoma group, was detected for 3 genes: 1) AR 
(2 isof) T–/A– (p = 0.0172), 2) PRLR T–/A– (p = 0.0088) 
and 3) SRD5A2 T–/A– (p = 0.0393), T+/A– (p = 0.0034), 
N+/A– (p = 0.0203).
Correlations of CPC with RE levels. The Spear-
man Rank Order Correlations (rs) analysis of CPC 
characteristics and RE of a set of genes in prostate 
adenocarcinomas has revealed a number of positive 
and negative correlations (Table 5A). For example, 
there is the reverse correlation between the Gleason 
score and RE of ESR2, VDR and SRD5A2: rs = –0.354, 
rs = –0.382 (p < 0.05), rs = –0.520 (p < 0.01), respec-
tively. Also, RE of GCR (in AG) and PRL showed the 
direct correlations with a tumor stage, and 8 genes — 
AR (1 isof), AR (2 isof), INSR (A isof), IGF1R, IGF1R tr, 
PRLR, VDR and SRD5A2 showed the negative corre-
lation with the tumor stage. Levels of the PSA in serum 
correlate negatively with RE of VDR and SRD5A2.
Correlations of RE levels between investigated 
genes. Investigation of RE correlations in prostate 
adenocarcinomas have shown 131 significant correla-
tions (from p < 0.0001 to p < 0.05) (Table 5B). Among 
them 34 have the highest score rs = |0,524–0,936| 
(from p < 0.0001 to p < 0.05). A maximal number 
of strong RE correlations showed INSR (A isof) — 
7 correlations, AR (1 isof), GCR (in AG), IGF1R, 
Table 5. Spearman Rank Order Correlations (rs) of CPC with genes RE (5A) and rs among genes RE in prostate adenocarcinomas (5B)
5A
AR 
(1 isof)
AR 
(2 isof) ESR1 ESR2
GCR
(AG isof)
GCR
(in AG)
GCR
(in B)
INSR
(A isof)
INSR
(B isof) IGF1R IGF1R tr PRLR PRL VDR SRD5A1 SRD5A2
GL 0.023 0.033 -0.238 -0.354 0.157 0.178 0.073 -0.157 -0.304 -0.146 -0.086 -0.009 0.007 -0.382 0.051 -0.520
Stage -0.381 -0.390 -0.235 0.142 0.261 0.377 -0.087 -0.478 -0.187 -0.441 -0.486 -0.326 0.437 -0.444 -0.005 -0.395
PSA, ng/ml -0.147 -0.097 -0.029 -0.271 -0.001 -0.016 -0.304 -0.178 -0.315 -0.319 -0.317 -0.254 -0.168 -0.409 0.067 -0.461
Age -0.154 -0.069 0.113 -0.011 0.211 0.187 0.357 -0.058 -0.066 -0.004 -0.090 -0.056 -0.052 0.261 -0.156 0.032
5B
Gene/ 
transcript T/ERG
AR
(1 isof)
AR
(2 isof) ESR1 ESR2
GCR
(AG isof)
GCR
(in AG)
GCR
(in B)
INSR
(A isof)
INSR
(B isof) IGF1R IGF1R tr PRLR PRL VDR SRD5A1 SRD5A2
AR (1 isof) 0.331 1.000
AR (2 isof) 0.486 0.665 1.000
ESR1 0.156 0.383 0.291 1.000
ESR2 -0.294 -0.049 -0.096 0.252 1.000
GCR 
(AG isof)
-0.118 0.017 0.043 0.461 0.297 1.000
GCR 
(in AG)
-0.239 -0.071 -0.025 0.267 0.457 0.855 1.000
GCR (in B) -0.007 0.204 0.322 0.307 0.322 0.539 0.584 1.000
INSR 
(A isof)
0.074 0.518 0.405 0.435 0.301 0.060 0.060 0.217 1.000
INSR 
(B isof)
-0.367 0.217 0.202 0.445 0.418 0.340 0.388 0.258 0.589 1.000
IGF1R 0.349 0.532 0.488 0.382 0.119 0.071 0.023 0.303 0.751 0.486 1.000
IGF1R tr 0.332 0.560 0.461 0.324 0.043 0.008 -0.051 0.230 0.755 0.450 0.936 1.000
PRLR 0.097 0.464 0.443 0.322 -0.079 0.087 -0.130 0.162 0.462 0.315 0.446 0.458 1.000
PRL -0.314 -0.263 -0.401 -0.293 0.093 -0.053 -0.051 -0.260 -0.391 -0.050 -0.371 -0.325 -0.038 1.000
VDR -0.001 0.291 0.280 0.340 0.241 0.063 0.025 0.247 0.536 0.278 0.248 0.237 0.232 -0.250 1.000
SRD5A1 0.194 -0.033 -0.041 -0.091 0.134 -0.029 0.125 -0.163 0.256 0.079 0.249 0.304 -0.227 -0.136 -0.035 1.000
SRD5A2 -0.222 0.319 0.058 0.328 0.505 -0.038 -0.023 0.080 0.424 0.491 0.422 0.398 0.329 -0.029 0.406 0.091 1.000
CDH1 0.125 0.439 0.374 0.124 0.116 -0.136 -0.153 0.311 0.601 0.296 0.716 0.631 0.367 -0.335 0.304 0.118 0.429
CDH2 -0.358 0.272 0.155 0.118 0.125 0.518 0.530 0.289 0.120 0.311 -0.007 -0.064 0.253 0.156 0.049 -0.138 0.116
CASP3 -0.045 0.492 0.389 0.130 0.104 0.261 0.314 0.340 0.332 0.348 0.248 0.239 0.220 -0.161 0.172 0.174 0.118
FN1 -0.250 0.069 0.099 0.343 0.168 0.499 0.520 0.362 0.039 0.364 -0.104 -0.140 0.001 -0.057 0.070 -0.229 -0.049
KRT18 0.449 -0.064 0.103 -0.313 -0.263 -0.512 -0.527 -0.328 0.063 -0.381 0.220 0.221 -0.051 -0.153 -0.055 0.258 -0.174
OCLN 0.467 0.631 0.516 0.150 -0.177 -0.190 -0.246 0.044 0.634 0.079 0.619 0.619 0.276 -0.268 0.326 0.267 -0.009
MKI67 0.317 0.356 0.430 -0.094 -0.128 -0.248 -0.161 -0.085 0.315 -0.090 0.140 0.186 0.087 -0.129 0.408 0.174 0.032
MMP2 -0.141 -0.053 -0.185 0.149 0.365 0.313 0.374 -0.124 -0.072 0.089 -0.350 -0.305 -0.331 0.056 0.137 0.205 0.205
MMP9 -0.027 -0.278 -0.175 0.462 0.355 0.213 0.099 -0.201 0.136 0.109 0.000 0.014 -0.078 0.014 0.208 0.162 0.211
NKX3-1 0.231 0.540 0.538 0.071 -0.038 -0.104 -0.105 0.366 0.562 0.212 0.632 0.592 0.495 -0.293 0.351 0.064 0.307
PSA 0.338 0.346 0.304 -0.330 -0.434 -0.658 -0.717 -0.307 0.168 -0.305 0.299 0.356 0.202 -0.215 -0.087 0.160 0.037
VIM -0.235 -0.235 -0.444 0.209 0.034 0.268 0.203 -0.316 -0.101 0.226 -0.201 -0.125 -0.164 0.244 -0.116 0.296 0.027
XIAP 0.077 0.572 0.524 0.235 0.101 0.177 0.191 0.427 0.562 0.349 0.416 0.439 0.389 -0.178 0.355 0.064 0.084
PCA3 0.344 0.151 0.380 -0.092 -0.315 -0.341 -0.388 0.042 0.193 -0.111 0.408 0.402 0.095 -0.304 -0.124 0.054 -0.257
HOTAIR -0.290 0.025 0.020 0.133 0.006 0.549 0.469 0.293 -0.053 0.203 -0.136 -0.163 0.300 0.260 0.019 -0.509 -0.157
SCHLAP1 0.338 -0.047 0.071 -0.421 -0.536 -0.477 -0.545 -0.440 -0.169 -0.587 -0.118 -0.098 -0.148 -0.057 -0.258 0.148 -0.445
Notes: p < 0.0001 (dark blue bold type), p < 0.001 (dark blue bold+italic type), p < 0.01 (red bold type), p < 0.05 (red).
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IGF1R tr — 6 correlations. This big number of correla-
tions confirms robust relationships between gene ex-
pression profiles and the close connections pathways, 
where these genes belong to.
Expression profiling of adenocarcinomas. 
To determine the putative molecular subtypes of the 
prostate adenocarcinomas, showing the certain gene 
expression profile, the K-means clustering was per-
formed, with analysis of RE of all of the studied genes 
and CPC (Gleason score and tumor stages) in the 
adenocarcinoma group. We found three specific clus-
ters (Fig. 2, Table 6), that included 33 out of 37 cancer 
samples (89%). These clusters showed the significant 
differences in RE of 21 out of 33 transcripts. The larg-
est distance is between clusters 1 and 3. All three 
clusters consist of tumors with the various Gleason 
scores (6, 7, 9).
The cluster 1 contains 12 samples with the 
TMPRSS2/ERG fusion. Also, in this group the highest 
expression of AR, epithelial markers (CDH1, NKX3-1, 
OCLN) and prostate cancer markers (PSA, PCA3, 
KRT18, SCHLAP1) is detected.
The cluster 3 contains the tumors with the highest 
Gleason score and a tumor stage index. By other words, 
the cluster 3 consists of the most aggressive tumors. 
This assumption is supported by the RE data. For exam-
ple, in this group we found the lowest expression of AR, 
epithelial markers (CDH1, OCLN, NKX3-1), SRD5A2, 
INSR (A and B) and IGF1R, and the high levels of PRL, 
lncRNA SCHLAP1 and HOTAIR, and also of mesenchy-
mal markers (VIM, FN1, MMP2). We have to mention, 
however, that the cluster 3 contains the lowest number 
of samples with the fusion — only 2 out of 8.
The gene expression profile in cluster 2 has a mixed 
pattern. For example, several epithelial and luminal 
markers, such as KRT18, PCA3 and PSA show the 
lowest expression, and other genes, namely mesen-
chymal markers CDH2, MMP2, FN1 and VIM are highly 
expressed.
DISCUSSION
The TMPRSS2-ERG  fusion transcript iso-
form 2 (EF194202.1) was first detected in prostate 
tumor samples by Lapointe et al. [23]. It is known that 
formation of this fusion transcript leads to overex-
pression of the ERG protein, which is involved in the 
signaling pathways associated with prostate cancer 
development [24, 25]. We wanted to enlighten the 
influence of this fusion on expression of some prostate 
cancer-associated receptors, enzymes and EMT-
associated genes. Thus, in paired adenocarcinoma/
CNT samples we have found the specific changes 
in RE in cancers with the fusion for 5 genes, whereas 
RE alterations for tumors without fusion were found 
only for 2 genes. The high level of ESR1 in tumors 
where the fusion was detected was associated with 
faster cancer progression [14].
In the present work we found among adenocar-
cinomas, CNT and adenomas that the ESR1 and 
SRD5A2 genes showed altered expression regard-
Table 6. Prostate adenocarcinomas RE means of clusters and statistical significant differences between them
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Fig. 2. Prostate adenocarcinomas RE profiling by K-means clustering
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less presence of the TMPRSS2-ERG fusion, while 
AR, MMP9 and HOTAIR were affected only in cases 
with no fusion, and expression of KRT18, PCA3 and 
SCHLAP1 were changed in adenocarcinomas with the 
fusion. Noteworthy, in adenomas we have detected 
the highest SRD5A2 RE levels. It is known that in-
creased SRD5A2 in adenomas provokes hyperplasia 
extension through NF-kB and AR isoform 7 conferring 
5α-reductase inhibitors resistance [26]. From other 
hand decreased levels of SRD5A2 in adenocarcinomas 
is associated with the enhanced cell migration and 
invasion [7]. Moreover, when SRD5A2 gene was re-
introduced, cell migration and invasion was inhibited, 
due to F-actin reorganization [27].
The high RE of lncRNA SCHLAP1 adenocarcino-
mas with the fusion predict unfavorable prognosis 
of disease [28]. The other lncRNA, HOTAIR when 
it expressed at the high levels in adenocarcinomas 
without fusion enhances proliferation and invasion 
at late stages of prostate cancer [29].
Earlier, we could not find a correlation between 
frequency of the fusion transcript detection and CPC, 
such as the Gleason score and stage [3], therefore 
we didn’t analyze TMPRSS2/ERG dependent changes 
for investigated genes in sample groups with different 
CPC. Now we found many correlations between CPC 
and RE of the genes, encoding receptors/enzymes 
in total group of adenocarcinomas. Eight out of ten 
significant (p < 0.01 to p < 0.05) correlations were 
negative, i.e. expression of these genes was decreas-
ing upon cancer progression. Furthermore, large 
quantity of the RE correlations of investigated genes 
allow us to perform the clustering of patients with ad-
enocarcinomas. We clustered prostate adenocarcino-
mas in three groups, based on the RE of 33 transcripts 
and also CPC characteristics.
Our experimental data on the RE profiles in pros-
tate adenocarcinomas are in concordance with the 
literature data [1, 2, 4]. It is widely accepted, that high 
expression of epithelial and luminal markers is usu-
ally accompanied by low expression of mesenchymal 
markers, and that we have observed in cluster 1. 
Noteworthy, we showed simultaneous high expression 
of the fusion transcript, PCA3 and NKX3-1 in one clus-
ter. It seems, that the fusion transcript and PCA3 do not 
influence negatively on expression of the tumor sup-
pression gene NKX3-1 and vice versa, as they belong 
to different pathways [1, 4]. At the other hand, the 
oncogenic PCA3 pathway [28, 30], probably, acts 
in parallel with the ERG pathway [23, 24].
To summarize subtyping data, it is essential to note 
specific cluster features. Cluster 1, which contains all 
fusion positive adenocarcinomas, has the most char-
acteristic expression profile namely fusion positive 
androgen dependent luminal subtype 1. Probably on-
cogenic pathways in this group are ERG and PCA3 [25, 
30] with high sensitivity to androgens, prolactin, IGF, 
INS stimulation oncogenic signaling.
We suppose that cluster 3 is another luminal 
prostate cancer subtype most of all it is fusion 
negative with androgen independent and castra-
tion resistant characteristics [30] (fusion negative 
androgen independent luminal subtype 2). It has 
molecular characteristic properties as the lowest 
expression of AR, epithelial markers (CDH1, OCLN, 
NKX3-1), SRD5A2, INSR (A and B) and IGF1R, high 
levels of mesenchymal markers (VIM, FN1, MMP2) 
and lncRNAs SCHLAP1 and HOTAIR. Moreover, in-
creasing RE of HOTAIR may cause the resistance for 
enzalutamide [29]. It is unique cluster with the highest 
PRL level, which could promote cancer progression 
through the PRL/STAT5 signaling pathway [15]. This 
is could mean prolactin administration of this cluster 
carcinogenesis.
We assume that cluster 2 is mixed stem-like an-
drogen dependent subtype. The lowest expression 
of some epithelial and luminal markers KRT18, PCA3, 
PSA and high expression for mesenchymal markers 
CDH2, MMP2, and tendency to RE growth of FN1, and 
VIM are characteristics of stem-like (basal) prostate 
cancer, in spite of high AR, CDH1, NKX3-1 RE. The 
highest RE levels of ESR1, SRD5A2, INSR B, PRLR 
and lncRNA HOTAIR give to this cluster peculiar car-
cinogenic property.
CONCLUSIONS
We have analyzed RE of 33 transcripts from 
27 genes to find alterations in prostate tumors, de-
pending on the presence or absence of the TMPRSS2/
ERG fusion. The significant differences of RE 
(p < 0.05) for 7 genes were detected, when compared 
adenocarcinomas and corresponding CNTs, using the 
2-ΔCT model. Five genes (ESR1, KRT18, MKI67, MMP9, 
PCA3) showed differential expression, when the paired 
samples with compared that were bearing the fusion; 
and only two genes (INSR (B isof) and HOTAIR) — 
when samples did not expressed the fusion product. 
When the 2-ΔΔCT model was used, the number of the 
differentially expressed genes were six (MMP9, MKI67, 
PCA3, SCHLAP1) and two (ESR1, HOTAIR) when the 
tissues expressed the fusion or regardless the pres-
ence of the fusion, respectively.
When adenomas, CNT and adenocarcinomas were 
compared, the KRT18, PCA3 and SCHLAP1 genes 
showed significant differences in RE in adenocarcino-
mas with the fusion. In adenocarcinomas without the 
fusion, such properties were shown by the AR (2 isof), 
MMP9, PRLR the HOTAIR genes. The ESR1 and 
SRD5A2 gene expression was altered in both types 
of adenocarcinomas.
Using the statistical analysis, we created three 
clusters of adenocarcinomas, based on gene RE and 
CPC characteristic. One of clusters was represented 
by adenocarcinomas with the TMPRSS2/ERG fusion. 
Further experiments are needed to confirm these data 
in a larger patient cohort.
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